Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant …
L Tanneau, MO Karlsson… - British journal of clinical …, 2020 - Wiley Online Library
Aims To externally validate an earlier characterized relationship between bedaquiline
exposure and decline in bacterial load in a more difficult‐to‐treat patient population, and to …
exposure and decline in bacterial load in a more difficult‐to‐treat patient population, and to …
[HTML][HTML] Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label …
M Cevik, LC Thompson, C Upton, VC Rolla… - The Lancet Infectious …, 2024 - thelancet.com
Background The current tuberculosis (TB) drug development pipeline is being re-populated
with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to …
with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to …
Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis
New regimens based on two or more novel agents are sought to shorten or simplify
treatment of tuberculosis (TB). Pretomanid (PMD) is a nitroimidazole in phase 3 trials that …
treatment of tuberculosis (TB). Pretomanid (PMD) is a nitroimidazole in phase 3 trials that …
Daily dosing for bedaquiline in patients with tuberculosis
DH Salinger, JR Nedelman, C Mendel… - Antimicrobial agents …, 2019 - Am Soc Microbiol
The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in
adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) …
adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) …
Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis …
K Walter, LHM Te Brake, AK Lemm… - Journal of …, 2024 - academic.oup.com
Background New and shorter regimens against multi-drug resistant tuberculosis (TB) remain
urgently needed. To inform treatment duration in clinical trials, this study aimed to identify …
urgently needed. To inform treatment duration in clinical trials, this study aimed to identify …
Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
MA Lyons - CPT: Pharmacometrics & Systems Pharmacology, 2021 - Wiley Online Library
Clinical development of combination chemotherapies for tuberculosis (TB) is complicated by
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
partial or restricted phase II dose‐finding. Barriers include a propensity for drug resistance …
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future
J Pasipanodya, T Gumbo - Antimicrobial agents and …, 2011 - Am Soc Microbiol
Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science and clinical trial
simulations have not been adequately applied to the design of doses and dose schedules of …
simulations have not been adequately applied to the design of doses and dose schedules of …
Translational model‐informed approach for selection of tuberculosis drug combination regimens in early clinical development
BO Susanto, SG Wicha, Y Hu… - Clinical …, 2020 - Wiley Online Library
The development of optimal treatment regimens in tuberculosis (TB) remains challenging
due to the need of combination therapy and possibility of pharmacodynamic (PD) …
due to the need of combination therapy and possibility of pharmacodynamic (PD) …
[HTML][HTML] Tradeoffs in introduction policies for the anti-tuberculosis drug bedaquiline: a model-based analysis
A Kunkel, FG Cobelens, T Cohen - PLoS medicine, 2016 - journals.plos.org
Background New drugs for the treatment of tuberculosis (TB) are becoming available for the
first time in over 40 y. Optimal strategies for introducing these drugs have not yet been …
first time in over 40 y. Optimal strategies for introducing these drugs have not yet been …
[PDF][PDF] Efficacy of bedaquiline, pretomanid, moxifloxacin & PZA (BPaMZ) against DS-& MDR-TB
R Dawson, K Harris, A Conradie, D Burger… - … on Retroviruses and …, 2017 - serve.mg.co.za
Background New anti-tuberculosis (TB) regimens are needed to treat drug sensitive (DS)
and multi-drug resistant (MDR) TB. NC-005 is an ongoing Phase 2b open-label, partly …
and multi-drug resistant (MDR) TB. NC-005 is an ongoing Phase 2b open-label, partly …